Rx for the future

Since the turn of the century, the life sciences sector has been experiencing profound evolution. Digital technologies that are already permeating the industry are set to fundamentally change the way new drugs and therapies are researched, developed, tested, deployed and consumed by patients. The underlying economics of the industry are also ripe for significant change. Vastly improved capabilities such as real-time monitoring and individualized medicine not only become technically feasible, but also dramatically less costly and more efficient. By embracing such change, life sciences companies can position themselves both to secure short-term finances and gain long-term industry benefits. We call this process Digital ReinventionTM.

Featured findings

49% of surveyed life sciences executives report that traditional value chains are being replaced with new value models
48% of surveyed life sciences executives say that boundaries between their industry and others are blurring
55% of surveyed life sciences executives say that competition is coming from new and unexpected places

About the authors

Sunanda Saxena

Sunanda Saxena
Associate Partner and Leader for Connected Health
IBM Watson Health Consulting

Julie Bowser

Julie Bowser
Global Life Sciences Industry Executive
IBM Global Markets

Heather Fraser

Heather Fraser
Global Lead for Healthcare and Life Sciences
IBM Institute for Business Value

Anthony Marshall

Anthony Marshall
Research Director, IBM Institute for Business Value
IBM Global Business Services

Read related IBM reports

Digital reinvention in action

Digital reinvention in action

What to do and how to make it happen

Digital reinvention

Digital reinvention

Preparing for a very different tomorrow

Prescribing a digital transformation for life sciences

Prescribing a digital transformation for life sciences

Your cognitive future in life sciences

A healthy outlook

A healthy outlook

Digital Reinvention in healthcare

Contact IBV

Want more information?